These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2924375)

  • 21. Phase I study of tauromustine administered in a weekly schedule.
    Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
    Eur J Cancer; 1993; 29A(13):1901-2. PubMed ID: 8260251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
    Smyth JF; Hardcastle JD; Denton G; Alderson D; Grace RH; Mansi JL; Yosef HM; Nordle O; Lauri H; Wählby S
    Ann Oncol; 1995 Nov; 6(9):948-9. PubMed ID: 8624301
    [No Abstract]   [Full Text] [Related]  

  • 24. Degradation of tauromustine (TCNU) in aqueous solutions.
    Loftsson T; Baldvinsdóttir J
    Acta Pharm Nord; 1992; 4(3):129-32. PubMed ID: 1418640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCNU in adenocarcinoma of the lung: a phase II study with divided doses.
    Sørensen JB; Bach F; Dombernowsky P; Vibe-Petersen J; Hansen HH
    Ann Oncol; 1990 Jul; 1(4):299-300. PubMed ID: 2265139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antitumor effect of a novel nitrosourea, tauromustine, at intravenous administration in rat. Cure of hepatomas.
    Roos G; el Hag IA; Christensson PI; Stenram U
    Anticancer Res; 1991; 11(5):1763-6. PubMed ID: 1837442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of tauromustine, a water-soluble nitrosourea compound on NMU-1 murine lung tumor.
    Pratesi G; Savi G
    Oncology; 1989; 46(2):132-5. PubMed ID: 2710478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic studies on 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). III. Pharmacokinetics of a new nitrosourea antitumor agent TA-077 in humans (a phase I study).
    Hayashida K; Miura Y; Arai Y; Takeyama S; Wakui A; Yokoyama M; Kanamaru R; Majima H; Taguchi T; Ohmichi M
    J Pharmacobiodyn; 1987 Oct; 10(10):523-7. PubMed ID: 3440914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma.
    Hill SR; Pollard LA; Bibby MC
    Anticancer Res; 1992; 12(6B):2169-75. PubMed ID: 1295464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of a novel nitrosourea, tauromustine, in the rat.
    Seidegård J; Grönquist L; Gunnarsson PO
    Biochem Pharmacol; 1990 May; 39(9):1431-6. PubMed ID: 2334443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
    Bibby MC; Double JA; Morris CM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCNU: a ray of hope for designer nitrosoureas?
    Workman P
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1823-8. PubMed ID: 3325292
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved antitumor effect of the nitrosourea drugs tauromustine (TCNU) and carmustine (BCNU) on a rat liver adenocarcinoma after hepatic arterial administration with degradable starch microspheres.
    Roos G; el Hag IA; Teder H; Stenram U
    Anticancer Res; 1991; 11(1):13-6. PubMed ID: 2018346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of tauromustine in malignant glioma.
    Gregor A; Rampling R; Aapro M; Malmström P; Whittle IR; Rye R; Stewart M; Sellar R; Demierre B; Ironside JW
    Eur J Cancer; 1992; 28A(12):1959-62. PubMed ID: 1419289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.
    Tranchand B; Lucas C; Biron P; Giroux B; Gordon B; Richards R; Solere P; Roux N; Evene E; Mornex F
    Cancer Chemother Pharmacol; 1993; 32(1):46-52. PubMed ID: 8462123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer.
    Taal BG; Ten Bokkel Huinink WW; Rodenhuis S
    Eur J Cancer; 1993; 29A(13):1916-7. PubMed ID: 8260256
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II study of TCNU in advanced breast cancer.
    Dombernowsky P; Clavel M; Smyth JF; Howell A; van Glabekke M; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1377-8. PubMed ID: 3181260
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines.
    Roed H; Vindeløv LL; Spang-Thomsen M; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1987; 19(4):315-8. PubMed ID: 3036388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.